For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...

The appointments are “a direct response to where our clients need us most,” Michael Maslansky, CEO of m+p, said in a ...

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across ...

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

RevMed’s leadership, too, highlighted the significance of Rasonque’s approval in a call with investors yesterday.

On Wednesday, the U.S. Court of Appeals for the Fifth Circuit affirmed (PDF) a previous ruling in district court rebuffing ...

Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis (EoE) as ...

Bristol Myers Squibb, by way of its RayzeBio unit, has taken a big step in furthering its commitment to radiopharmaceuticals, ...

The Trump administration looks set to unveil a new slate of most favored nation (MFN) drug pricing deals with several ...

Frontier Large Language Models have improved. More data became accessible. Neither solved the hardest questions. Here's what ...

By Alicia Cowley, MD, MBA, Medical Director, Phreesia Network Solutions | Endemic media and broad reach each do half the job.

Artis BioSolutions opened the doors to a new manufacturing center in Bilbao, Spain, that expands the CDMO’s production ...